Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. I-Mab
  6. News
  7. Summary
    IMAB   US44975P1030

I-MAB

(IMAB)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

I-Mab Biopharma Mulls Dual-Listing on Shanghai Star Board & HKEX

08/01/2021 | 12:46am EDT

I-Mab Biopharma is weighing a dual-listing on Shanghai STAR board and HKEX (00388.HK), reported IFR under Reuters. The company expects to complete the listings by 2022, believing that the dual-listing could help capturing investors in the onshore market, the report added.


ę S&P Capital IQ 2021
All news about I-MAB
09:08aI-Mab Secures Approval to Conduct Phase 2 Trial of Enoblituzumab Combo Therapy for Soli..
MT
08:01aI-MAB : Announces Acceptance of IND Application from China NMPA for Phase 2 Clinical Trial..
PR
09/20I-MAB(NASDAQGM : IMAB) added to FTSE All-World Index
CI
09/15China's biotech sector comes of age with big licensing deals, global ambitions
RE
09/13I-MAB : Added to FTSE ESG Index Series
PR
09/02I-MAB : Added to FTSE Russell Global Equity Index Series
PR
09/01I MAB : HC Wainwright Adjusts I-Mab's Price Target to $95 from $75, Keeps Buy Rating
MT
08/31I MAB : H1 Loss Widens
MT
08/31I MAB : Provides Business and Corporate Updates and Reports Financial Results for the Six ..
PU
08/31I-Mab Announces Consolidated Earnings Results for the Six Months Ended June 30, 2021
CI
More news
Analyst Recommendations on I-MAB
More recommendations
Financials (USD)
Sales 2021 78,2 M - -
Net income 2021 -209 M - -
Net cash 2021 611 M - -
P/E ratio 2021 -34,4x
Yield 2021 -
Capitalization 5 389 M 5 389 M -
EV / Sales 2021 61,1x
EV / Sales 2022 24,6x
Nbr of Employees 228
Free-Float 98,7%
Chart I-MAB
Duration : Period :
I-Mab Technical Analysis Chart | IMAB | US44975P1030 | MarketScreener
Technical analysis trends I-MAB
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 15
Last Close Price 70,02 $
Average target price 94,73 $
Spread / Average Target 35,3%
EPS Revisions
Managers and Directors
Hua Qiong Shen Chief Executive Officer & Director
Zheru Zhang President & Director
Jielun Zhu Chief Financial Officer & Director
Jing Wu Zang Chairman
Lili Qian Vice President-Operations
Sector and Competitors
1st jan.Capi. (M$)
I-MAB48.50%5 389
JOHNSON & JOHNSON3.68%429 542
ROCHE HOLDING AG9.24%319 352
PFIZER, INC.19.37%244 283
NOVO NORDISK A/S48.08%227 557
ELI LILLY AND COMPANY34.09%205 250